Pyxis Oncology PYXS 深 沪
交易中 08-27 10:48:30 美东时间
3.30
-0.040
-1.20%
华盛通- 最 高3.31
- 今 开3.31
- 成交量 5.53万股
- 最 低 3.25
- 昨 收 3.34
- 总市值 27.52万
- 52周最高 5.55
- 市盈率 静 --
- 换手率 0.07%
- 52周最低 1.03
- 委 比 -97.24%
- 总股本 8.34万
- 历史最高 19.00
- 量 比 0.52
- 振 幅 1.80%
- 历史最低 0.8332
- 每 手 1
- 风险率 1.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pyxis Oncology Files Prospectus For Offering 39.2M Common Shares On Behalf Of Selling Shareholders
https://www.sec.gov/Archives/edgar/data/1782223/000119312526359246/pyxs-20260820.htm
08-21 04:31
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
Pyxis Oncology Q2 EPS $(0.40) Misses $(0.35) Estimate
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35) by 14.29 percent. This is a 33.33 percent decrease over losses of $(0.30) per share from the same period last year.
08-13 19:14
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Pyxis Oncology reported Q2 2026 financial results, highlighting advancements in its MICVO clinical programs. The company expects to report updated monotherapy data for 2L+ R/M HNSCC in Fall 2026 and combination data with pembrolizumab in Q4 2026. Pyxis completed a $114M private placement, providing $50M in upfront proceeds to extend its cash runway into Q2 2027. The company's cash balance as of June 30, 2026, was $34.5M, and net loss for the quar...
08-13 11:00
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
Wells Fargo Initiates Coverage On Pyxis Oncology with Overweight Rating, Announces Price Target of $12
Wells Fargo analyst Derek Archila initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Overweight rating and announces Price Target of $12.
08-03 21:15
Leerink Partners Maintains Outperform on Pyxis Oncology, Lowers Price Target to $7
Leerink Partners analyst Jeffrey La Rosa maintains Pyxis Oncology (NASDAQ:PYXS) with a Outperform and lowers the price target from $9 to $7.
07-02 20:34
Pyxis Oncology Commences ~$50M Offering Of 19.6M Common Shares At $2.551/Share
Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has entered into definitive securities purchase agreements for a private placement expected to result in gross proceeds of approximately $50 mi...
06-30 19:39
Pyxis Oncology shares are trading lower. The company reported Q1 financial results.
Pyxis Oncology shares are trading lower. The company reported Q1 financial resu...
05-15 03:49
Pyxis Oncology Q1 EPS $(0.37), Inline
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.37) per share which met the analyst consensus estimate. This is a 5.71 percent decrease over losses of $(0.35) per share from the same period last year.
05-14 19:16
